Immunotherapy

• 

  Subject Areas on Research

  • A Blueprint to Advance Colorectal Cancer Immunotherapies. 
  • A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors. 
  • A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. 
  • A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. 
  • A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates. 
  • A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation. 
  • A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. 
  • A global approach to tumor immunology. 
  • A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. 
  • A multiphase immunotherapy regimen for human melanoma: clinical and laboratory results. 
  • A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. 
  • A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. 
  • A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma. 
  • A preliminary study utilizing viable HLA mismatched cultured glioma cells as adjuvant therapy for patients with malignant gliomas. 
  • A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. 
  • A promising cancer vaccine. 
  • A reevaluation of CD22 expression in human lung cancer. 
  • A self-assembling peptide acting as an immune adjuvant. 
  • A simple method to cure established tumors by inflammatory killing of normal cells. 
  • A single genetic locus determines the efficacy of serum therapy against murine adenocarcinoma 755a. 
  • A study of dendritic and endothelial cell interactions in colon cancer in a cell line and small mammal model. 
  • A urologic oncology roundtable discussion: issues to consider in choosing treatment for metastatic castration-resistant prostate cancer. 
  • ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers. 
  • AIDS and HIV infection. 
  • AIDS-related cytomegalovirus retinitis: lessons from the laboratory. 
  • Abnormalitieis of monocyte chemotaxis in patients with melanoma: effects of immunotherapy and tumor removal. 
  • Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrence. 
  • Active immunization with tumor cells transduced by a novel AAV plasmid-based gene delivery system. 
  • Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines. 
  • Active immunotherapy with transiently transfected cytokine-secreting tumor cells inhibits breast cancer metastases in tumor-bearing animals. 
  • Active specific immunotherapy of Dukes B2 and C colorectal carcinoma: comparison of two doses of the vaccine. 
  • Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. 
  • Adeno-associated virus vectors: potential applications for cancer gene therapy. 
  • Adenosine deaminase and purine nucleoside phosphorylase deficiencies: evaluation of therapeutic interventions in eight patients. 
  • Adjuvanted Immunotherapy Approaches for Peanut Allergy. 
  • Adoptive transfer and specific active immunization of patients with malignant melanoma. 
  • Advances and challenges: dendritic cell vaccination strategies for glioblastoma. 
  • Advances in immunotherapy for pancreatic cancer: 2013. 
  • Advances in myasthenia gravis. 
  • Advances in pediatric hematopoietic stem cell transplantation. 
  • Advances in the diagnosis and treatment of primary immunodeficiency diseases. 
  • Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas. 
  • Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients. 
  • An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. 
  • An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection. 
  • An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. 
  • Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. 
  • Anti-HIV-1 ADCC: clinical and therapeutic implications. 
  • Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. 
  • Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. 
  • Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA. 
  • Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. 
  • Antibody-based immunotherapy for malignant glioma. 
  • Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. 
  • Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. 
  • Aptamers in immunotherapy. 
  • Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. 
  • Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas. 
  • Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting. 
  • Augmentation of tumor-specific immunity by upregulation of apoptotic melanoma cell calreticulin expression. 
  • Autoimmune disorders of neuromuscular transmission. 
  • Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. 
  • Autologous lymph node cell-derived tumor-specific cytotoxic T-cells for use in adoptive immunotherapy of human melanoma. 
  • B cells in chronic graft-versus-host disease. 
  • B cells in the pathophysiology of myasthenia gravis. 
  • B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. 
  • B-lymphocyte contributions to human autoimmune disease. 
  • Biomarkers and correlative endpoints for immunotherapy trials. 
  • Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. 
  • Biomaterial interactions with the immune system. 
  • Bladder cancer. 
  • Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. 
  • Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. 
  • CD20: a regulator of cell-cycle progression of B lymphocytes. 
  • CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. 
  • CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. 
  • CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy. 
  • CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. 
  • CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. 
  • Can you tBID on it? 
  • Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award. 
  • Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. 
  • Cancer immunotherapy: harnessing the immune system to battle cancer. 
  • Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions. 
  • Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era. 
  • Carcinoma of the lung. 
  • Cell binding and tumor inhibiting functions of a new antihuman melanoma murine monoclonal antibody. 
  • Cellular and biological therapies of gastrointestinal tumors: overview of clinical trials. 
  • Certolizumab pegol. 
  • Challenges in the pursuit of immune tolerance. 
  • Chemoimmunotherapy's potential to impact paroxysmal nocturnal hemoglobinuria. 
  • Clinical applications of a peptide-based vaccine for glioblastoma. 
  • Clinical applications of dendritic cell vaccines. 
  • Clinical immunotherapy for brain tumors. 
  • Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models. 
  • Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma. 
  • Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. 
  • Combinations of Bevacizumab With Cancer Immunotherapy. 
  • Combining cancer vaccines with chemotherapy. 
  • Combining immunotherapy and radiotherapy for the STAR treatment. 
  • Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. 
  • Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. 
  • Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. 
  • Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy. 
  • Complement disorders and hereditary angioedema. 
  • Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. 
  • Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. 
  • Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. 
  • Continuous DC-CIK infusions restore CD8+ cellular immunity, physical activity and improve clinical efficacy in advanced cancer patients unresponsive to conventional treatments. 
  • Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses. 
  • Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer. 
  • Critical care perspective on immunotherapy in lung transplantation. 
  • Current immunotherapeutic strategies in colon cancer. 
  • Current immunotherapeutic strategies in malignant melanoma. 
  • Current management of melanoma. 
  • Current status of dendritic cell immunotherapy of malignancies. 
  • Cytokine and immuno-gene therapy for solid tumors. 
  • Cytokine expression in vivo during murine herpetic stromal keratitis. Effect of protective antibody therapy. 
  • DNA array-based gene profiling in tumor immunology. 
  • DNA-based immunotherapy to treat atopic disease. 
  • Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. 
  • Delivery of Synthetic mRNA Encoding FOXP3 Antigen into Dendritic Cells for Inflammatory Breast Cancer Immunotherapy. 
  • Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. 
  • Dendritic cell maturation in active immunotherapy strategies. 
  • Dendritic cell-based immunization for cancer therapy. 
  • Dendritic cell-based immunotherapy. 
  • Dendritic cell-tumor cell fusion vaccines. 
  • Dendritic cells activate antitumor immunity for malignant intracranial germ cell tumor: a case report. 
  • Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells. 
  • Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma. 
  • Developing treatment guidelines for myasthenia gravis. 
  • Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. 
  • Disorders of human leukocyte chemotaxis. 
  • Distant cutaneous granulomas after bacille Calmette-Guérin immunotherapy for malignant melanoma: case for direct infection. 
  • Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. 
  • Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses. 
  • Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. 
  • Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study. 
  • Driving an improved CAR for cancer immunotherapy. 
  • Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. 
  • Dysfunctional T cell metabolism in the tumor microenvironment. 
  • EGF mutant receptor vIII as a molecular target in cancer therapy. 
  • EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. 
  • EGFRvIII-targeted vaccination therapy of malignant glioma. 
  • Effect of Anti-C5a Therapy in a Murine Model of Early/Intermediate Dry Age-Related Macular Degeneration. 
  • Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases. 
  • Effect of adriamycin and Corynebacterium parvum in tumor-bearing mice: modulation of response to sheep red blood cells. 
  • Effective antibody therapy in herpes simplex virus ocular infection. Characterization of recipient immune response. 
  • Effects of hyperthermia and irradiation on the growth of mouse melanoma tumors following immunotherapy. 
  • Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. 
  • Emerging clinical applications of RNA. 
  • Emerging immunotherapies for glioblastoma. 
  • Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. 
  • Emerging therapeutics for ocular surface disease. 
  • Emerging treatment options for patients with castration-resistant prostate cancer. 
  • Engineering challenges for brain tumor immunotherapy. 
  • Enhanced dendritic cell antigen presentation in RNA-based immunotherapy. 
  • Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Evaluation in a pre-clinical model. 
  • Enhanced macrophage tumoricidal activity and tumor suppression or regression caused by heat-killed Candida albicans. 
  • Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. 
  • Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection. 
  • EpCAM: A new therapeutic target for an old cancer antigen. 
  • Epidermal growth factor receptor and variant III targeted immunotherapy. 
  • Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon. 
  • Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases. 
  • Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. 
  • Exercise as Adjunct Therapy in Cancer. 
  • Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer. 
  • Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. 
  • Fine tuning of immunometabolism for the treatment of rheumatic diseases. 
  • Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). 
  • From the RNA world to the clinic. 
  • Fulfilling the promise of immunotherapy. 
  • Future therapies for food allergy. 
  • Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms. 
  • Gene Expression Profile of Dendritic Cell-Tumor Cell Hybrids Determined by Microarrays and Its Implications for Cancer Immunotherapy. 
  • Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy. 
  • Gene therapy and pancreatic cancer. 
  • Gene therapy for prostate cancer. 
  • Gene- and cell-based approaches for neurodegenerative disease. 
  • Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. 
  • Generation of human IgG, IgA, and IgM anti-melanoma monoclonal antibodies utilizing lymphocytes of an actively immunized melanoma patient. 
  • Global role of the immune system in identifying cancer initiation and limiting disease progression. 
  • Gold nanoparticles-mediated photothermal therapy and immunotherapy. 
  • Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations. 
  • Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. 
  • Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. 
  • Graft-versus-leukemia in man: relationship of acute and chronic graft-versus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation. 
  • Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines. 
  • Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-Sponsored Expert Panel Report. 
  • HIV antibodies for treatment of HIV infection. 
  • High dose immunotherapy with stem cell rescue in severe systemic sclerosis: an idea that is moving forward. 
  • Highly conserved gene expression profiles in humans with allergic rhinitis altered by immunotherapy. 
  • Host-Directed Therapies for Tuberculosis. 
  • Human T cells specifically activated against autologous malignant melanoma. 
  • Human cytotoxic T cells specific for autologous melanoma cells: successful generation from lymph node cells in seven consecutive cases. 
  • Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T-cells. 
  • Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection. 
  • Hyperthermia-regulated immunogene therapy. 
  • Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. 
  • Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. 
  • Identification of a tumor associated antigen that can induce tumor specific cytotoxicity. 
  • Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. 
  • Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. 
  • IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. 
  • Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab. 
  • Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. 
  • Immune Checkpoint Inhibitors for Brain Metastases. 
  • Immune Checkpoint Inhibitors in Gliomas. 
  • Immune therapies for neuroblastoma. 
  • Immuno-prophylaxis and -therapy of C-type oncorna viral diseases in mice and cats. 
  • Immunobiologic aspects of the brain and human gliomas. A review. 
  • Immunobiology of human gliomas. 
  • Immunobiology of primary intracranial tumors. 
  • Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. 
  • Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. 
  • Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy. 
  • Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. 
  • Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. 
  • Immunomodulation for glioblastoma. 
  • Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines. 
  • Immunonanoshells for targeted photothermal ablation of tumor cells. 
  • Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity. 
  • Immunotherapeutic targeting of Wilms' tumor protein. 
  • Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity. 
  • Immunotherapy advances for glioblastoma. 
  • Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer. 
  • Immunotherapy and monoclonal antibody therapies. 
  • Immunotherapy approaches for malignant glioma from 2007 to 2009. 
  • Immunotherapy approaches in the treatment of malignant brain tumors. 
  • Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? 
  • Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma. 
  • Immunotherapy for Brain Tumors. 
  • Immunotherapy for HIV. 
  • Immunotherapy for Resected Pulmonary Metastases. 
  • Immunotherapy for primary brain tumors: no longer a matter of privilege. 
  • Immunotherapy for refractory pulmonary infection after adult cardiac surgery: immune dysregulation syndrome. 
  • Immunotherapy in neonatal sepsis: advances in treatment and prophylaxis. 
  • Immunotherapy in selected patients with Down syndrome disintegrative disorder. 
  • Immunotherapy of B-cell malignancies with genetically engineered human CD8+ natural killer T cells. 
  • Immunotherapy of brain tumors. 
  • Immunotherapy of cancer using cytokine gene-modified tumor vaccines. 
  • Immunotherapy of established murine squamous cell carcinoma using fused dendritic-tumor cell hybrids. 
  • Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. 
  • Immunotherapy of malignant brain tumors. 
  • Immunotherapy of type 1 diabetes: where are we and where should we be going? 
  • Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. 
  • Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. 
  • Immunotherapy using allogeneic squamous cell tumor-dendritic cell fusion hybrids. 
  • Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. 
  • Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. 
  • Immunotherapy with tumor vaccines for the treatment of malignant gliomas. 
  • Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. 
  • Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. 
  • Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. 
  • Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate. 
  • In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: relevance to immunotherapy of prostate carcinoma. 
  • In vivo evaluation of cell mediated immunity against human melanoma. 
  • Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. 
  • Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. 
  • Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. 
  • Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine. 
  • Induction of cellular immunity to Coccidioides immitis after sensitization with dinitrochlorobenzene. 
  • Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. 
  • Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. 
  • Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy. 
  • Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells. 
  • Inhibition of the growth of human melanoma xenografts in nude mice by human tumor-specific cytotoxic T-cells. 
  • Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors. 
  • Innovations and challenges in renal cancer: consensus statement from the first international conference. 
  • Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. 
  • Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). 
  • Interleukin-10: An Immune-Activating Cytokine in Cancer Immunotherapy. 
  • Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo. 
  • Interleukin-2 immunotherapy and AIDS-related cytomegalovirus retinitis. 
  • Interleukin-2 immunotherapy of murine cytomegalovirus retinitis during MAIDS correlates with increased intraocular CD8+ T-cell infiltration. 
  • Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. 
  • Investigative studies in the diagnosis and treatment of melanoma. 
  • Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. 
  • Irradiation and immunotherapy: From concept to the clinic. 
  • Keyhole limpet hemocyanin: structural and functional characterization of two different subunits and multimers. 
  • Lessons from two trials of mycophenolate mofetil in myasthenia gravis. 
  • Lethal "thin" malignant melanoma. Identifying patients at risk. 
  • Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity. 
  • Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases. 
  • Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. 
  • Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. 
  • MCA106 fibrosarcoma cells transduced with granulocyte/macrophage colony-stimulating factor are not superior to the wild-type cells in suppressing the growth of hepatic metastases. 
  • MRP3: a molecular target for human glioblastoma multiforme immunotherapy. 
  • Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. 
  • Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas. 
  • Malignant melanoma and pregnancy. 
  • Mammalian C-type oncornaviruses: relationships between viral structural and cell-surface antigens and their possible significance in immunological defense mechanisms. 
  • Management of allergic rhinitis in the working-age population. 
  • Management of recurrent melanoma of the extremity. 
  • Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. 
  • Mechanism of immune response during immunotherapy. 
  • Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. 
  • Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy. 
  • Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes. Implications of a renewable source of precursors for adoptive cellular immunotherapy. 
  • Memory T cells. 
  • Messenger RNA (mRNA) nanoparticle tumour vaccination. 
  • Metabolic Barriers to T Cell Function in Tumors. 
  • Metabolic reprogramming of the immune response in the tumor microenvironment. 
  • Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies. 
  • Migration of human dendritic cells after injection in patients with metastatic malignancies. 
  • Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review. 
  • Modulation of specific active immunization against murine melanoma using recombinant cytokines. 
  • Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation. 
  • Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines. 
  • Monitoring cellular immune responses to cancer immunotherapy. 
  • Monoclonal antibodies for brain tumour treatment. 
  • Monoclonal antibodies to different epitopes on a prostate tumor-associated antigen. Implications for immunotherapy. 
  • Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. 
  • Monoclonal antibody therapy of human gliomas: current status and future approaches. 
  • Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. 
  • Murine cytomegalovirus retinitis during retrovirus-induced immunodeficiency (MAIDS) in mice: interleukin-2 immunotherapy correlates with increased intraocular levels of perforin mRNA. 
  • Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease. 
  • Myasthenia gravis: management of myasthenic crisis and perioperative care. 
  • Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. 
  • NCCN Guidelines Insights: Melanoma, Version 3.2016. 
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. 
  • NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. 
  • NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. 
  • Natural killer cell responses to viral infection. 
  • Neuro-ophthalmic side effects of molecularly targeted cancer drugs. 
  • Neuromuscular Disease in the Neurointensive Care Unit. 
  • New and emerging treatments for advanced prostate cancer. 
  • New drug development in metastatic prostate cancer. 
  • New frontiers of immunotherapy for HIV. 
  • New treatments for men with castration-resistant prostate cancer: can we move from small steps to giant leaps? 
  • Non-Hodgkin's lymphomas. 
  • Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Non-cholinergic strategies for treating and preventing Alzheimer's disease. 
  • Non-specific and specific active immunotherapy in a B16 murine melanoma system. 
  • Non-specific and specific immunotherapy in patients with melanoma. 
  • Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates. 
  • Novel chemotherapies in development for management of castration-resistant prostate cancer. 
  • Novel immunotherapeutic strategies in development for renal cell carcinoma. 
  • Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy. 
  • Novel therapeutic approaches to advanced prostate cancer. 
  • Novel therapies for pancreatic adenocarcinoma. 
  • Novel therapies for the treatment of advanced prostate cancer. 
  • On the double: Early immunotherapy speeds recovery of ocular myasthenic weakness. 
  • Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus. 
  • Oncolytic polio virotherapy of cancer. 
  • One-unit versus two-unit cord-blood transplantation for hematologic cancers. 
  • Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era. 
  • Optimizing dendritic cell function by genetic modification. 
  • Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution. 
  • Optimizing the use of regulatory T cells in allotransplantation: recent advances and future perspectives. 
  • Overview of melanoma vaccines and promising approaches. 
  • PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. 
  • PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. 
  • Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. 
  • Payer database and geospatial analysis to evaluate practice patterns in treating allergy in North Carolina. 
  • Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques. 
  • Pharmacological inhibition of TGFβ as a strategy to augment the antitumor immune response. 
  • Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas. 
  • Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. 
  • Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. 
  • Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. 
  • Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. 
  • Possibilities of immunotherapy and gene therapy for malignant melanoma. 
  • Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. 
  • Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer. 
  • Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope. 
  • Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. 
  • Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer. 
  • Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy. 
  • Preparation of peptide-loaded dendritic cells for cancer immunotherapy. 
  • Program death-1 immune checkpoint and tumor microenvironment in malignant liver tumors. 
  • Promising vaccines for treating glioblastoma. 
  • Properties of mouse leukemia viruses. XIX. Effective antibody therapy of AKR leukemia occurs independently of virus neutralization and produces long-term changes in the virus status of the thymus. 
  • Prospect of rindopepimut in the treatment of glioblastoma. 
  • Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. 
  • Prospects for the immunological management of lethal tumors. 
  • Prospects for treatment of human retrovirus-associated diseases. 
  • Prospects for vaccine protection against HIV-1 infection and AIDS. 
  • Prospects of immune checkpoint modulators in the treatment of glioblastoma. 
  • Prostate cancer gene therapy. 
  • Putting Provenge in perspective. 
  • Putting Provenge in perspective. 
  • RNA transfected dendritic cells as cancer vaccines. 
  • RNA-transfected dendritic cells in cancer immunotherapy. 
  • Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma. 
  • Rationale for hypoxia assessment and amelioration for precision therapy and immunotherapy studies. 
  • Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer. 
  • Recent developments in therapeutic cancer vaccines. 
  • Recombinant Poliovirus for Cancer Immunotherapy. 
  • Recurrent Glioblastoma Treated with Recombinant Poliovirus. 
  • Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. 
  • Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. 
  • Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy. 
  • Reply to M.C. Chamberlain. 
  • Reprograming immunity to food allergens. 
  • Rescuing imperfect antigens for immuno-oncology. 
  • Response to immunotherapy in a patient with Landau-Kleffner syndrome and GRIN2A mutation. 
  • Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. 
  • Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme. 
  • Role of antibodies to murine leukemia virus p15E transmembrane protein in immunotherapy against AKR leukemia: a model for studies in human acquired immunodeficiency syndrome. 
  • Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. 
  • Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. 
  • Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience. 
  • Sequential CT Findings in Patients With Non-small-cell Lung Cancer Receiving Nivolumab. 
  • Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. 
  • Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. 
  • Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. 
  • Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy. 
  • Specific active immunotherapy for melanoma. 
  • Specific cytotoxic antibody in the sera of patients with melanoma. 
  • Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma. 
  • Successful tumour immunotherapy: possible role of antibodies to anti-inflammatory factors produced by neoplasms. 
  • Supramolecular peptide vaccines: tuning adaptive immunity. 
  • Surrogate markers of effective anti-tumor immunity. 
  • Surrogate markers of response to cancer immunotherapy. 
  • Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy. 
  • Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. 
  • Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. 
  • Systemic cytokine immunotherapy for experimental cytomegalovirus retinitis in mice with retrovirus-induced immunodeficiency. 
  • Systemic strategies for prostate cancer. 
  • Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. 
  • T helper subsets in allergic eye disease. 
  • T-cell Dysfunction in Glioblastoma: Applying a New Framework. 
  • T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance. 
  • TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. 
  • Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). 
  • Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). 
  • Targeting B-cells mitigates autoimmune diabetes in NOD mice: what is plan B? 
  • Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. 
  • Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. 
  • Targeting cell surface F1F0 ATP synthase in cancer therapy. 
  • Targeting the TLR9-MyD88 pathway in the regulation of adaptive immune responses. 
  • Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. 
  • Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. 
  • Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. 
  • Temperature matters! And why it should matter to tumor immunologists. 
  • Tempering allorecognition to induce transplant tolerance with chemically modified apoptotic donor cells. 
  • Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. 
  • The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. 
  • The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. 
  • The Safety of available immunotherapy for the treatment of glioblastoma. 
  • The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma. 
  • The challenges of checkpoint inhibition in the treatment of multiple myeloma. 
  • The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. 
  • The current state of immunotherapy for gliomas: an eye toward the future. 
  • The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. 
  • The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. 
  • The effects of leukemosuppressive immunotherapy on thymic infectious cell centers in AKR mice. 
  • The evolving role of gene-based treatment in surgery. 
  • The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. 
  • The future of rheumatoid arthritis treatment. 
  • The gasteointestinal oncology clinic. A multidisciplinary approach to cancer diagnosis and management at a University Medical Center. 
  • The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. 
  • The immunologic constant of rejection. 
  • The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. 
  • The management of bee hives. 
  • The management of desmoid tumors. 
  • The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. 
  • The role of bone marrow and thymic elements in the initiation and spread of virus production in the AKR thymus. 
  • The role of tregs in glioma-mediated immunosuppression: potential target for intervention. 
  • The treatment of colorectal carcinoma: standard chemotherapy and beyond. 
  • Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. 
  • Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology. 
  • Thoracic empyema associated with recurrent colon cancer: report of a case and review of the literature. 
  • Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines. 
  • Toward effective immunotherapy for the treatment of malignant brain tumors. 
  • Toward improved effectiveness of bladder cancer immunotherapy. 
  • Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity. 
  • Translational Research Working Group developmental pathway for immune response modifiers. 
  • Treatment options for newly diagnosed patients with chronic lymphocytic leukemia. 
  • Treatment outcomes of surgery, antifungal therapy and immunotherapy in ocular and vascular human pythiosis: a retrospective study of 18 patients. 
  • Tumor antigens in astrocytic gliomas. 
  • Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. 
  • Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine. 
  • Tumor-associated macrophages: implications in cancer immunotherapy. 
  • Tumor-dendritic cell fusion as a basis for cancer immunotherapy. 
  • Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. 
  • Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. 
  • Turning lemons into lemonade: learning from negative studies in cancer immunotherapy. 
  • Type B CpG oligodeoxynucleotides induce Th1 responses to peanut antigens: modulation of sensitization and utility in a truncated immunotherapy regimen in mice. 
  • Understanding the response to immunotherapy in humans. 
  • Updates in adjuvant systemic therapy for melanoma. 
  • Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial. 
  • VEGF inhibitors in cancer therapy. 
  • Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. 
  • What potential does plasmonics-amplified synergistic immuno photothermal nanotherapy have for treatment of cancer? 
  • Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management. 
  • Whole blood cells loaded with messenger RNA as an anti-tumor vaccine. 
  • X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity. 
  • [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis]. 
  • [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part II: radiobiological and immunologic strategies]. 
  • [Basis for a specific-active immunotherapy in malignant melanoma]. 
  • [In vivo evaluation of cellular immunity in melanoma patients against melanoma]. 
  • cDNA arrays and the enigma of melanoma immune responsiveness. 
  • miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Bowes Rickman, Catherine, Professor of Ophthalmology, Cell Biology
  • Buckley, Rebecca Hatcher, James Buren Sidbury Distinguished Professor of Pediatrics, in the School of Medicine, Immunology
  • Choi, Taewoong, Medical Instructor in the Department of Medicine, Duke Cancer Institute
  • Chongsathidkiet, Pakawat, Student, Pathology
  • Cohen-Wolkowiez, Michael, Professor of Pediatrics, Pediatrics, Infectious Diseases
  • Farsiu, Sina, Paul Ruffin Scarborough Distinguished Associate Professor of Engineering, Electrical and Computer Engineering
  • Fecci, Peter Edward, Associate Professor of Neurosurgery, Immunology
  • Ferrari, Guido, Associate Professor of Surgery, Molecular Genetics and Microbiology
  • Inman, Brant Allen, Cary N. Robertson, MD, Associate Professor, Surgery, Urology
  • Lee, Walter T, Associate Professor of Surgery, Radiation Oncology
  • MacLeod, Amanda S, Associate Professor in Dermatology, Immunology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Mosca, Paul Joseph, Associate Professor of Surgery, Surgical Oncology
  • Mowery, Yvonne Marie, Butler Harris Assistant Professor in Radiation Oncology, Radiation Oncology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Shariff, Afreen Idris, Assistant Professor of Medicine, Medicine, Endocrinology, Metabolism, and Nutrition
  • Steinbach, William J., Samuel L. Katz Distinguished Professor of Pediatrics, Duke Innovation & Entrepreneurship
  • Zhong, Xiaoping, Professor of Pediatrics, Immunology